Interestingly, especially in the latter group of patients, a beneficial effect was observed in those receiving G-CSF primary prophylaxis (as per local policy), as shown by reduced rates of neutropenia and NF episodes (40% vs. 78% and 30% vs. 38%, respectively). This evidence concerns the gene CSF3 and neutropenia.